Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Procyon Corporation, along with its affiliated entities, specializes in the development and distribution of proprietary medical solutions. Their primary focus is on addressing various skin conditions, including pressure and stasis ulcers, general wounds, dermatitis, inflammation, and other dermatological issues, predominantly within the United States. The company offers a diverse array of products. Under the AMERIGEL brand, they provide sophisticated skin and wound healing items such as hydrogel dressings, post-operative surgical kits, saline wound rinses, and protective lotions, in addition to hand sanitizer. Their HELIX3 line features Bioactive Collagen products, available in both powder and matrix forms. For comprehensive wound management, the AMERX brand includes various dressing types like calcium alginate, foam, gauze, and hydrocolloid, as well as complete wound care kits containing components like collagen matrix, collagen powder, foam, and hydrogel. Furthermore, Procyon markets compression garments under the EXTREMIT-EASE name. These offerings are distributed through multiple channels: to institutional clients such as hospitals, wound care clinics, nursing homes, home health agencies, and medical practitioners via distributors, and directly to individual consumers through online sales, direct purchases, and independent or chain pharmacies. Founded in 1987, the company's operations are headquartered in Clearwater, Florida.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITD.